| ACT | Prolonged activated clotting time |
| AF | Atrial fibrillation |
| APTT | Activated partial thromboplastin time |
| ASA | Acetylsalicylic acid |
| ATC Code | Anatomical therapeutic chemical classification system |
| ATP | Adenosine triphosphate |
| COVID-19 | Coronavirus disease 2019 |
| DGF | Amino acid sequence Asp-Phe-Gly |
| DOAC | Direct oral anticoagulants |
| dTT | Diluted thrombin time |
| ECM | Extracellular matrix |
| ECT | Ecarin clotting time |
| EMA | European Medicines Agency |
| ERK | Extracellular signal-regulated kinases |
| FDA | Food and Drug Administration |
| FGF | Fibroblast growth factor |
| FGFR | Fibroblast growth factor feceptor |
| Flt-3 | Receptor type tyrosine protein kinase FLT3 |
| GP IIb/IIIa | Glycoprotein IIb/IIIa |
| HAS-BLED | Bleeding risk in atrial fibrillation score |
| HAS-BLED | hypertension, age, stroke, prior major bleeding, labile INR, abnormal liver or kidney function, drugs |
| IC50 | Half-maximal inhibitory concentration |
| ICD-10-CM | International Classification of Diseases, Tenth Revision, Clinical Modification |
| ILD | Interstitial lung diseases |
| IPF | Idiopathic pulmonary fibrosis |
| LCK | Lymphocyte-specific protein tyrosine kinase |
| LMWH | Low-molecular weight heparin |
| LYN | Tyrosine-protein kinase Lyn |
| MAPK | Mitogen-activated protein kinase |
| MEK | Mitogen-activated protein kinase |
| NSCLC | Non-small cell lung cancer |
| ORBIT | Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
| P2Y12 | Receptor for endogenous nucleotides Type 12 |
| PCC | Prothrombin complex factor |
| PDB ID | Protein Data Bank identification code |
| PDGF | Platelet derived growth factor |
| PDGFR | Platelet derived growth factor receptors |
| P-gl | P-Glycoprotein |
| PI3K | Phosphoinositide 3-Kinase |
| PT | Prothrombin time |
| Raf | RAF kinases, serine/threonine specific protein kinase |
| Ras | Ras protein, guanosine nucleotide binding protein |
| RTK | Receptor tyrosine kinases |
| Src | Src kinase, nonreceptor tyrosine kinase |
| TDM | Therapeutic drug monitoring |
| TF | Tissue factor |
| TFPI | Tissue factor pathway inhibitor |
| TGA | Therapeutic Goods Administration |
| TT | Thrombin time |
| TxA2 | Thromboxane A2 |
| UFH | Unfractionated heparin |
| VEDF | Vascular endothelial growth factor |
| VEDFR | Vascular endothelial growth factor receptor |
| VKA | Vitamin K antagonist |